Monsenso has signed an agreement with Awakn Life Sciences, a global biotech company

Monsenso has signed an agreement with Awakn Life Sciences, a global biotech company

Monsenso has signed an agreement with, a global biotech company, to support the company’s medical psychedelic treatments. Awakn Life Sciences is a global biotech company that leads the field of psychedelic medicine for the treatment of addiction. In October 2021 commenced the implementation of the Monsenso Digital Health Solution in Awakn Life Sciences clinical practice as a tool for supporting patients throughout their treatment while capturing real-world patient insights to inform clinical decision-making and personalised treatment.

Mental illness and addiction are some of the biggest public health challenges facing the global community.

Nearly one billion people worldwide suffer from mental illness, for which there are too few effective treatments available beyond coping strategies and treating symptoms. With global spending on mental health estimated to reach $16 trillion by 2030 (as measured by lost economic output)[1], it is critical that effective new treatments are developed to address the current gaps. Psychedelic-assisted therapy has emerged as a potential solution to this treatment vacuum. In the early 20th century, these substances were severely restricted and had a negative connotation. Today, however, a growing body of evidence and urgent unmet patient needs have led clinicians and regulators to consider them as a viable treatment option.

Psychedelic-Assisted Psychotherapy represents a paradigm shift in psychiatric treatment

Psychedelic drugs are substances that alter perception and mood and affect various cognitive processes. When used in conjunction with psychotherapy, they can put patients in a temporary state where they can better process memories, emotions, and past traumas[2], allowing for processing that enables subjects to let go of things that have previously troubled them[3]. For the same reason, psychedelic-assisted psychotherapy has shown effective in treating historically difficult-to-treat illnesses[4] and is today considered a promising game-changer in psychiatric treatment[5,6,7].

While psychedelics have spurred great interest in the life science industry, only a few psychedelic companies are currently treating patients in the clinical setting. Awakn Life Sciences launched the UK’s first psychedelic-assisted clinic in Bristol, followed by London and Manchester, offering evidence-based psychedelic therapies for addiction and other mental health indications, and has also opened a clinic in Oslo, Norway with plans to scale across Europe quickly.

In October 2021, Awakn Life Science commenced implementation of the Monsenso Digital Health Solution in its clinical practice to support patients throughout their treatment journey and to capture real-world data to inform clinicians’ decision making for personalised patient support and management.

“We are excited to work with Awakn Life Science to support new treatment options for people who have experienced insufficient treatment results. We look forward to partnering with Awakn Life Sciences and be part of their growth journey” says CEO of Monsenso, Thomas Lethenborg.

Awakn’s CEO, Anthony Tennyson added “There’s such a critical need to provide solutions and hope to people suffering from mental illnesses and addiction. We’re excited to partner with Monsenso to better engage with clients throughout their treatment, gain insights to help inform clinical decisions and improve health outcomes, and generate insights that inform our research and treatment development programs”.

About Awakn Life Science Awakn Life Sciences is a publicly-traded (NEO: AWKN) (OTCQB: AWKNF) biotechnology company with clinical operations; researching, developing, and delivering psychedelic medicine to better treat Addiction. Awakn’s team consists of worldleading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies and enabling technologies to treat Addiction.

About Monsenso Monsenso is an innovative technology company offering a digital health solution for mental health and behavioral disorders. Our mission is to help provide better mental health to more people at lower costs. Our solution helps optimise the treatment of mental disorders and gives a detailed overview of an individual’s mental health through the collection of outcome, adherence and behavioural data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. Based on continuous research and development, our team is committed to developing solutions that fit seamlessly into the lives of individuals, increase their quality of life and improve the efficacy of mental health treatment. To learn more visit www.monsenso.com

For additional information contact:
Bettina van Wylich-Muxoll
Chief Marketing Officer
marketing@monsenso.com
Monsenso

Sources:

[1] https://www.weforum.org/agenda/2020/10/mental-health-day-covid19-coronavirus-global/

[2] https://www.health.harvard.edu/blog/back-to-the-future-psychedelic-drugs-in-psychiatry-202106222508

[3] Jennifer Mitchell, neuroscientist and professor in the departments of neurology, psychiatry and behavioral sciences at the University of California San Francisco.

[4] Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development

[5] https://www.health.harvard.edu/blog/back-to-the-future-psychedelic-drugs-in-psychiatry-202106222508

[6] https://www.scientificamerican.com/article/a-renaissance-for-psychedelics-could-fill-a-long-standing-treatment-gap-forpsychiatric-disorders/

[7] Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development

MHealth, a scalable and cost-efficient solution for mental healthcare

MHealth, a scalable and cost-efficient solution for mental healthcare

Approximately 450 million people worldwide suffer from mental disorders. One fifth of teenagers under the age of 18 suffer from developmental, emotional or behavioural problems, and one in eight have a mental disorder. Five of the ten leading causes of disability worldwide are psychiatric conditions, including depression, alcohol abuse, schizophrenia, and obsessive compulsive disorder. [1]

The Institute of Medicine Report has proposed a framework of mental health intervention for mental illness based on the classification and the public health distinctions between primary, secondary and tertiary prevention. [1]

Primary prevention focuses on promoting mental well-being, and decreasing adverse conditions such as child abuse, violence, discrimination, poverty, and lack of education to the general population. It also seeks to target individuals or subgroups of the population whose risk of developing a mental illness is higher due to biological, psychological or social risk factors.

Secondary prevention seeks to reduce the symptoms and decrease the number of episodes through early detection and treatment. [1]

Tertiary prevention includes interventions that reduce disability, enhance rehabilitation, and prevent relapses and recurrences of the illness. [1]

A Dutch study found a 50% reduction in the incidence of major depression among mildly depressed primary care patients who received a stepped-care intervention, compared with the incidence among primary care patients who received treatment as usual. Other studies showed that low-dose antidepressants or problem-solving therapy helped reduce the incidence of major and minor depression in post-stroke patients. [2]

Preventive measures such as mental health promotion and early intervention are the most cost-effective way to tackle mental illness on a global scale. Research reveals that common mental disorders such as depression and anxiety can be prevented. For instance, Cognitive Behavioural Therapy (CBT) has proven to be useful for people who already have mild depressive symptoms.

During the last few years, technology has crossed a new frontier in mental health support and data collection. Mobile health (mHealth technology) provides doctors, researchers and the general population with new ways to monitor a patient’s progress, access self-help tools, and increase understanding of mental wellbeing.

Mobile mental health support can be very simple but effective. For example, the Monsenso mHealth solution which consists of a smartphone app for patients and carers and web portal for clinicians uses self-reported data and the device’s built-in sensors to collect patient information. Based on the self-reported data, the Monsenso smartphone app identifies any triggers or warning signs, and it notifies patients and clinicians that help is needed before a crisis occurs. The Monsenso smartphone app also provides users with self-help tools that are always available in case of an emergency.

Although there are many mental health apps available on both the iTunes and Android app stores, this new technology includes a lot of uncertainty. There isn’t enough information on the quality, security and effectiveness of the different apps available, which can confuse clinicians and users.

The advantages of mental health apps

Experts believe that technology has a lot of potential for users and clinicians. A few of the benefits of mobile care include:

  • Convenience:Treatment can take place anytime and anywhere (e.g. at home in the middle of the night or on a bus on the way to work) and may be ideal for those who have trouble with in-person appointments.
  • Anonymity:Clients can seek treatment options without involving other people.
  • An introduction to care: Technology may be a good first step for those who have avoided mental health care in the past.
  • Lower cost: Some apps are free or cost less than traditional care.
  • Service to more people: Technology can help mental health providers offer treatment to people in remote areas or to many people in times of sudden need (for example following a natural disaster or terror attack).
  • Interest: Some technologies might be more appealing than traditional treatment methods, which may encourage clients to continue therapy.
  • 24-hour monitoring: Technology can provide round-the-clock monitoring and self-help tools or interventions.
  • Consistency: Technology can offer the same treatment plan to all users.
  • Support: Technology can complement traditional therapy by extending an in-person session, reinforcing new skills, and providing support and monitoring. [3]

Trends in smartphone apps for mental health

  • Self-management apps
    Users enter self-reported data into the app so it can provide feedback. For example, medication reminders, stress-coping strategies or sleep problems. Some apps can also track sensor data and may help users monitor their progress and receive feedback.
  • Apps to improve thinking skills and skills training
    Apps that help users with improved thinking skills (cognitive remediation) and learn new coping or thinking skills. For example, they provide educational videos about anxiety management or the importance of social support. Additionally, users might pick up some new skills and use the app to practice those skills. This type of app may feel a little bit like a game, and often target people with severe mental illness.
  • Supported care
    This type of app allows users to interact with a trained health care provider or a peer support group who can offer guidance in case of an emergency.
  • Monitoring and data collection
    This type of mental health app can collect two types of data. On one hand, it gathers data using the sensors built into smartphones such as movement patterns, social interactions, behaviour at different times of the day, speech patterns and more. On the other hand, it collects self-reported data in the form of a mood diary or electronic questionnaire.

Although mental health apps may not replace mental health professionals, they allow clinicians to provide better support to more people regardless of their geographical location.

References:

[1] Prevention of mental disorders. Effective interventions and policy options. World Health Organisation. http://www.who.int/mental_health/evidence/en/prevention_of_mental_disorders_sr.pdf

[2] The future looks promising for mental health prevention. Psychiatric News. Joan Arehart-Treichel. 2013 (January 18). http://psychnews.psychiatryonline.org/doi/10.1176/appi.pn.2013.10b1

[3] Technology and the future of mental health treatment. National Institute of Mental Health. http://www.nimh.nih.gov/health/topics/technology-and-the-future-of-mental-health-treatment/index.shtml

The importance of early intervention in the recovery process

The importance of early intervention in the recovery process

Early intervention is critical to treating mental illness before it can cause tragic results such as serious impairment, unemployment, homelessness, poverty, and suicide [1].

The identification of mental illness and its treatment, as early as possible, represents a high priority. The early detection and treatment of mental illness promote recovery, independence, and self-sufficiency, as well as facilitating social activities and employment opportunities [2].

It is estimated that 100,000 adolescents and young adults in the United States alone experience a first episode of psychosis every year. The early phase of psychotic illness is widely viewed as a critical opportunity for indicated prevention, and a chance to alter the downward trajectory and poor outcomes associated with serious mental disorders such as schizophrenia. The timing of treatment is critical; short and long-term outcomes are better when individuals begin treatment close to the onset of psychosis. Numerous studies find a substantial delay between the onset of psychotic symptoms and the initiation of treatment. In the U.S., treatment is typically delayed between one and three years, suggesting that many people experiencing first episodes of psychosis are missing a critical opportunity to benefit from early intervention [3].

Early identification and rapid referral are essential to shortening the duration of untreated psychosis and pre-empting functional deterioration. The World Health Organization advocates reducing the duration of untreated psychosis to three months or less by addressing “bottlenecks” in the pathway from early psychosis identification to initiation of specialty care [3].

To support early intervention, in 2009, the National Institute of Mental Health (NIMH), implemented a research project to change the prognosis of schizophrenia through aggressive treatment in the earliest stages of illness.Recovery After an Initial Schizophrenia Episode (RAISE) is designed to reduce the likelihood of long-term disability that people with schizophrenia often experience. It aims to help people with the disorder lead productive, independent lives. At the same time, it aims to reduce the financial impact on the public systems often tapped to pay for the care of people with schizophrenia [4].

In 2011, RAISE began conducting a full-scale, randomized controlled trial comparing two different ways of providing treatment to people experiencing the early stages of schizophrenia and related disorders. Both types of treatment emphasize early intervention but feature different approaches for initiating and coordinating care. Treatment may include personalized medication treatment, individual resiliency training, and supportive services, such as family psychoeducation and education or employment assistance [5]. The RAISE study, expected to be completed by August 2016, aims to emphasize the importance of early intervention.

The Monsenso mHealth solution can help healthcare providers to closely monitor patients who have experienced a first episode of mental illness.

After experiencing a first episode, the healthcare provider can encourage the patient to use the Monsenso mHealth solution. This will enable the clinician to monitor the individual on a continuous basis, and react if symptoms arise.

With the Monsenso user app, patients can fill in self-assessments on a daily basis. These self-assessments include information on the patient’s behaviour and symptoms related to his mental health. Furthermore, the solution collects sensor data through sensors in the patient’s smartphone, and this combined with the self-assessment will help the healthcare provider to continuously monitor the patient, and support intervention at a very early stage. Early warning signs and automatic triggers can be set to indicate to the health care provider that proactive intervention is needed, if for example a patient sleeps too little or feels too distressed.

Early intervention and continuous monitoring can maximize a person’s chances of a fast recovery, self-sufficiency, and living a high-quality life including the possibility to pursue and education and maintain a stable job.

References:

[1] Directors Blog: SAMHSA and NIMH partner to support early intervention for serious mental illness. P. Hyde and T. Insel. National Institute of Mental Health Blog (2014, June 17) http://www.nimh.nih.gov/about/director/2014/samhsa-and-nimh-partner-to-support-early-intervention-for-serious-mental-illness.shtml

[2] Early intervention and recovery for young people with early psychosis: consensus statement. J. Bertolote and P. McGorry. British Journal of Psychiatry (2005). http://bjp.rcpsych.org/content/bjprcpsych/187/48/s116.full.pdf

[3] Evidence based treatment for first episode of psychosis: Components of coordinated specialty care. PHD R. K. Heinssen. RAISE NIMH (2014, April 14). http://www.nimh.nih.gov/health/topics/schizophrenia/raise/nimh-white-paper-csc-for-fep_147096.pdf

[4] Raise Project Overview. National Institute of Mental Health. (2009)http://www.nimh.nih.gov/health/topics/schizophrenia/raise/index.shtml

[5] NIMH RAISE Project makes progress as team refines research approach. National Institute of Mental Health. (2011, August 9) http://www.nimh.nih.gov/news/science-news/2011/nimh-raise-project-makes-progress-as-teams-refine-research-approaches.shtml